ADP-ribosylation is an important post-translational protein modification (PTM) that regulates diverse biological processes. ADP-ribosyltransferase diphtheria toxin-like 10 (ARTD10, also known as PARP10) mono-ADP-ribosylates acidic side chains and is one of eighteen ADP-ribosyltransferases that catalyze mono- or poly-ADP-ribosylation of target proteins. Currently, no enzyme is known that reverses ARTD10-catalyzed mono-ADP-ribosylation. Here we report that ARTD10-modified targets are substrates for the macrodomain proteins MacroD1, MacroD2 and C6orf130 from Homo sapiens as well as for the macrodomain protein Af1521 from archaebacteria. Structural modeling and mutagenesis of MacroD1 and MacroD2 revealed a common core structure with Asp102 and His106 of MacroD2 implicated in the hydrolytic reaction. Notably, MacroD2 reversed the ARTD10-catalyzed, mono-ADP-ribose-mediated inhibition of glycogen synthase kinase 3β (GSK3β) in vitro and in cells, thus underlining the physiological and regulatory importance of mono-ADP-ribosylhydrolase activity. Our results establish macrodomain-containing proteins as mono-ADP-ribosylhydrolases and define a class of enzymes that renders mono-ADP-ribosylation a reversible modification.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/nsmb.2521 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recurrent Loss of Macrodomain Activity in Host Immunity and Viral Proteins.
Pathogens
May 2023
Department of Molecular Biology, School of Biological Sciences, University of California-San Diego, La Jolla, CA 92093, USA.
Protein post-translational modifications (PTMs) are an important battleground in the evolutionary arms races that are waged between the host innate immune system and viruses. One such PTM, ADP-ribosylation, has recently emerged as an important mediator of host antiviral immunity. Important for the host-virus conflict over this PTM is the addition of ADP-ribose by PARP proteins and removal of ADP-ribose by macrodomain-containing proteins.
View Article and Find Full Text PDFDTX3L E3 ligase targets p53 for degradation at poly ADP-ribose polymerase-associated DNA damage sites.
iScience
April 2023
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
P53 is a master transcriptional regulator and effector of the DNA damage response (DDR) that localizes to DNA damage sites, in part, via an interaction with PARP1. However, the mechanisms that regulate p53 abundance and activity at PARP1-decorated DNA damage sites remain undefined. The PARP9 (BAL1) macrodomain-containing protein and its partner DTX3L (BBAP) E3 ligase are rapidly recruited to PARP1-PARylated DNA damage sites.
View Article and Find Full Text PDFUnlabelled: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a global pandemic that resulted in more than 6-million deaths worldwide. The virus encodes several non-structural proteins (Nsps) that contain elements capable of disrupting cellular processes. Among these Nsp proteins, Nsp3 contains macrodomains, e.
View Article and Find Full Text PDFEvolution of a histone variant involved in compartmental regulation of NAD metabolism.
Nat Struct Mol Biol
December 2021
Cancer and Leukaemia Epigenetics and Biology Program, Josep Carreras Leukaemia Research Institute, Badalona, Spain.
Article Synopsis
- - NAD metabolism is crucial for all life forms, with a focus on how its consumption is regulated between the nucleus and mitochondria to maintain energy balance.
- - The study explores the evolution of macroH2A1.1, a histone variant that helps limit nuclear NAD usage by inhibiting a specific enzyme in vertebrate cells, and traces its origin back to early protists.
- - Through analyzing the structure and lifecycle of the protist Capsaspora owczarzaki, the research identifies key evolutionary changes in macroH2A that relate to NAD regulation, offering insights that could have therapeutic implications.
NAD+-consuming enzymes in immune defense against viral infection.
Biochem J
December 2021
Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853, U.S.A.
The COVID-19 pandemic reminds us that in spite of the scientific progress in the past century, there is a lack of general antiviral strategies. In analogy to broad-spectrum antibiotics as antibacterial agents, developing broad spectrum antiviral agents would buy us time for the development of vaccines and treatments for future viral infections. In addition to targeting viral factors, a possible strategy is to understand host immune defense mechanisms and develop methods to boost the antiviral immune response.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!